Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Maura Gasparetto to Humans

This is a "connection" page, showing publications Maura Gasparetto has written about Humans.

 
Connection Strength
 
 
 
0.111
 
  1. Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA, Seligman P. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019 05; 80:1-10.
    View in: PubMed
    Score: 0.018
  2. Gasparetto M, Smith CA. ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. Chem Biol Interact. 2017 Oct 01; 276:46-51.
    View in: PubMed
    Score: 0.016
  3. Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. 2017 06; 102(6):1054-1065.
    View in: PubMed
    Score: 0.016
  4. Gasparetto M, Sekulovic S, Zakaryan A, Imren S, Kent DG, Humphries RK, Vasiliou V, Smith C. Varying levels of aldehyde dehydrogenase activity in adult murine marrow hematopoietic stem cells are associated with engraftment and cell cycle status. Exp Hematol. 2012 Oct; 40(10):857-66.e5.
    View in: PubMed
    Score: 0.011
  5. Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 2004 Sep; 292(1-2):59-71.
    View in: PubMed
    Score: 0.007
  6. Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 09 06; 13(9):2032-2049.
    View in: PubMed
    Score: 0.006
  7. Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030.
    View in: PubMed
    Score: 0.006
  8. Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, Jordan CT. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Rep. 2019 04 02; 27(1):238-254.e6.
    View in: PubMed
    Score: 0.005
  9. Matsumoto A, Arcaroli J, Chen Y, Gasparetto M, Neumeister V, Thompson DC, Singh S, Smith C, Messersmith W, Vasiliou V. Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer. Br J Cancer. 2017 Nov 07; 117(10):1537-1543.
    View in: PubMed
    Score: 0.004
  10. Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016 07 07; 19(1):23-37.
    View in: PubMed
    Score: 0.004
  11. Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015; 815:349-59.
    View in: PubMed
    Score: 0.003
  12. Imren S, Heuser M, Gasparetto M, Beer PA, Norddahl GL, Xiang P, Chen L, Berg T, Rhyasen GW, Rosten P, Park G, Moon Y, Weng AP, Eaves CJ, Humphries RK. Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Blood. 2014 Dec 04; 124(24):3608-12.
    View in: PubMed
    Score: 0.003
  13. Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci. 2014 Mar; 1310:58-68.
    View in: PubMed
    Score: 0.003
  14. Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, Laakso NM, Lagoo AS, Storms R, Smith C, Nevins JR. A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet. 2009 Sep; 5(9):e1000640.
    View in: PubMed
    Score: 0.002
  15. Le Meur N, Rossini A, Gasparetto M, Smith C, Brinkman RR, Gentleman R. Data quality assessment of ungated flow cytometry data in high throughput experiments. Cytometry A. 2007 Jun; 71(6):393-403.
    View in: PubMed
    Score: 0.002
  16. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007 May; 21(5):926-35.
    View in: PubMed
    Score: 0.002
  17. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 Aug 15; 63(16):5126-35.
    View in: PubMed
    Score: 0.002
  18. Gasparetto C, Gasparetto M, Morse M, Rooney B, Vredenburgh JJ, Long GD, Rizzieri DA, Loftis J, Chao NJ, Smith C. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine. 2002 Apr 07; 18(1):8-19.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)